CG Oncology (CGON) Enterprise Value (2023 - 2026)
CG Oncology's (CGON) quarterly Enterprise Value came in at -$1.1 billion in Q1 2026, down 56.33% YoY from -$2.5 billion in Q1 2025, and down 45.02% on a QoQ basis from -$742.2 million in Q4 2025.
CG Oncology (CGON) Enterprise Value (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Enterprise Value data on file, last reported at -$1.1 billion in Q1 2026.
- Quarterly Enterprise Value fell 56.33% year-over-year to -$1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.1 billion (down 56.33% YoY) and the FY2025 annual result came in at -$742.2 million, changed 0.02% from the prior year.
- Enterprise Value fell to -$1.1 billion in Q1 2026, from -$742.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$187.7 million in Q4 2023 to a low of -$1.1 billion in Q1 2026.
- A 4-year average of -$643.8 million and a median of -$670.7 million in 2025 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value slumped 295.37% — and 2025, when it slipped 0.02%.
- Tracing CGON's Enterprise Value over 4 years: stood at -$187.7 million in 2023, then tumbled by 295.37% to -$742.0 million in 2024, then declined by 0.02% to -$742.2 million in 2025, then slumped by 45.02% to -$1.1 billion in 2026.
- The last three Enterprise Value figures came in at -$1.1 billion (Q1 2026), -$742.2 million (Q4 2025), and -$680.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | -1.03 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.03 Bn |
| Mar 31, 2026 | -1.08 Bn |
| Dec 31, 2025 | -742.16 Mn |
| Sep 30, 2025 | -680.26 Mn |
| Jun 30, 2025 | -661.05 Mn |
| Mar 31, 2025 | -688.43 Mn |
| Dec 31, 2024 | -742.00 Mn |
| Sep 30, 2024 | -540.71 Mn |
| Jun 30, 2024 | -552.88 Mn |
| Mar 31, 2024 | -566.51 Mn |
| Dec 31, 2023 | -187.67 Mn |